

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2018/083137 A1

(43) International Publication Date

11 May 2018 (11.05.2018)

(51) International Patent Classification:

A23L 33/105 (2016.01) A61K 36/81 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2017/077993

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

02 November 2017 (02.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16196794.8 02 November 2016 (02.11.2016) EP

(71) **Applicant:** PROVEXIS NATURAL PRODUCTS LIMITED [GB/GB]; Prospect House 58 Queens Road, Reading Berkshire RG1 4RP (GB).

(72) **Inventors:** MUSSLER, Bernd; c/o DSM Nutritional Products Ltd, Patent Department, Wurmisweg 576, 4303 Kaiseraugst (CH). RAEDERSTORFF, Daniel; c/o DSM Nutritional Products Ltd, Patent Department, Wurmisweg 576, 4303 Kaiseraugst (CH). RICHARD, Nathalie; c/o DSM Nutritional Products Ltd, Patent Department, Wurmisweg 576, 4303 Kaiseraugst (CH).

(74) **Agent:** BANFORD, Paul, Clifford; Bioscience IP Limited, 11 Lostock Hall Road, Poynton, Cheshire SK12 1DP (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** WATER SOLUBLE TOMATO EXTRACT PROTECTS AGAINST ADVERSE EFFECTS OF AIR POLLUTION

(57) **Abstract:** The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.

WATER SOLUBLE TOMATO EXTRACT PROTECTS AGAINST ADVERSE EFFECTS OF AIR POLLUTION

BRIEF DESCRIPTION OF THE INVENTION

This invention relates to the use of a water-soluble tomato extract (“WSTE”) to protect against adverse effects of air pollution on the body’s cardiovascular system.

BACKGROUND OF THE INVENTION

Air pollution comes in many forms. A common type of pollution is referred to as “particulate air pollution”, which contains pollution in the form of soot, gases and other matter which are in the form of tiny particles, termed “respirable particulate matter”. Respirable particulate matter is categorized by size, such as below 10 or 2.5 microns aerodynamic diameter (PM₁₀ or PM_{2.5}, respectively), or as nanoparticles (less than 100 nm diameter, or PM_{0.1}). These particles often come from vehicle emissions, particularly diesel fuel, or from diesel-powered machinery.

It has been shown that particulate matter is able to enter the blood stream and induce cytotoxic and inflammatory responses, and there is a recognized link between exposure to diesel emissions and cardiovascular disease. However, the actual mechanism of how this is accomplished is still not fully understood. See Solomon et al 2013 *J. Thromb Haemost* 11: 325-34; Tabor et al 2016 *Particle and Fibre Toxicology* 13:6 DOI 10.1186/s12989-016-0116-x; Lucking et al 2008 *European Heart J* 29: 3043-3051; and Hunter et al 2014 *Particle and Fibre Technology* 11:62 DOI 10.1186/s12989-014-0062-4.

Air pollution is a mixture of particulate matter (PM) and gaseous components. Numerous studies show that exposure to PM air pollution has adverse effect on cardiovascular health (Miller et al. 2012, Pope et al. 2015). Platelet activity/reactivity is linked to an increased risk of cardiovascular diseases especially thrombosis and will also contribute to the development of atherosclerosis. Platelet activity/reactivity can be increased by a number of factors notably air pollution. Thus, PM has been shown to promote arterial thrombosis and atherosclerosis through increased platelet activation.

Not all platelet anti-aggregation agents work via the same pathway, nor are anti-aggregation agents responsive to all aggregation stimuli. For example, clopidogrel (an anti-platelet pharmaceutical used in the secondary prevention of cardiovascular complications of atherosclerosis) can inhibit adenosine 5'-diphosphate (ADP) -induced platelet aggregation but not platelet aggregation induced by collagen or thrombin. (see Weber et al 1999 *British J Pharmacology* 126: 415-420). PM may stimulate platelet aggregation via a physical mechanism in addition to a physiological mechanism (such as the mechanism seen in oxygen radical -induced aggregation).

Water soluble tomato extracts which are lycopene-free have been described; see, e.g. WO2010/049707; WO10/049709, and WO99/55350 (all by Provexis Natural Products, Ltd). They are commercially available from DSM Nutritional Products, Switzerland under the registered trademark FRUITFLOW and FRUITFLOW 2. They have been described as having anti-platelet aggregation abilities, which are presumed to be due to the presence of nucleosides and other active agents in the extracts, such as adenosine, caffeic acid derivatives including chlorogenic acid, and flavonoids such as rutin and quercetin-3,4-glycoside.

It would be desirable to have a safe, effective nutraceutical, food or food supplement, nutraceutical or medicament which could help ameliorate the effects of particulate air pollution.

DETAILED DESCRIPTION OF THE INVENTION

It has been found, in accordance with this invention, that a water soluble tomato extract can protect the cardiovascular system against the adverse effects brought on by exposure to particulate air pollution. Thus, the invention concerns the use of a water soluble tomato extract (WSTE) for the maintenance of a healthy cardiovascular system, and/or to prevent platelet aggregation brought on by interaction with air pollution particulate matter.

According to a first aspect of the invention there is provided a composition comprising a Water soluble tomato extract for use in maintaining cardiovascular health, lessening the risk of developing a cardiovascular health problem, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject who is exposed, or is at risk of exposure, to particulate air pollution.

According to another aspect of this invention there is provided a method of maintaining cardiovascular health, lessening the risk of developing a cardiovascular health problem, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution comprising administering a protective amount of a water soluble tomato extract prior to or concomitant with exposure to air pollution particulate matter.

Another aspect of this invention provides the use of WSTE in the manufacture of a medicament, nutraceutical, food supplement or food for use in maintaining cardiovascular health, lessening the risk of developing a cardiovascular health problem, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject who is exposed, or is at risk of exposure, to particulate air pollution.

Another aspect of this invention provides a dosage form comprising a medicament, nutraceutical, food supplement or food comprising an effective amount of WSTE for protecting against the adverse effects of particulate air pollution.

The inventors believe that WSTE is effective for maintaining cardiovascular health because, as discussed below, WSTE decreases or minimizes the risk of platelet aggregation in a subject exposed to particulate air pollution. Thus, according to another aspect of the invention, there is provided a method of decreasing, or minimizing the risk of, platelet aggregation in a subject exposed to particulate air pollution comprising administering to the subject an effective amount of WSTE prior to or during exposure to particulate air pollution.

BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1 shows the effect of FRUITFLOW on the amount of aggregation (maximal % aggregation) induced by particulate matter. Details are in the Examples.

FIGURE 2 shows the effect of FRUITFLOW on the amount of aggregation (maximal % aggregation) induced by particulate matter and ADP (adenosine diphosphate)

DEFINITIONS

As used in the specification and claims, the following definitions apply:

Water Soluble Tomato Extract (“WSTE”): The WTSE used in this invention has the following properties:

- It is water soluble at room temperature, i.e. at 25°C. In preferred embodiments, the extracts also are soluble at lower temperatures as well (such as 15°C, 10°C or even as low as 4°C, although more stirring over a longer period of time may be required). The WSTE contains substantially no, or only negligible quantities of lycopene (less than 0.5% by dry weight, preferably less than 0.1% by dry weight).
- It is substantially free from water-insoluble particulate material (i.e. less than 0.1% by dry weight, preferably less than 0.01% by dry weight of particulate material).
- It may be in liquid or dry forms. In some forms, such as in the dry extract FRUITFLOW 2, the sugars have been removed, and the extract has been concentrated.

Particulate Air Pollution: This is air pollution which contains particles which are classified as nanoparticles, or have a particle size of PM_{2.5} or less. These size particles can be the result of “natural sources” such as volcanic emission, dust storms, forest fires, smoke from grassland fires and the like, or as a result of human activity such as automotive emissions, manufacturing emissions or other activities, including smoking.

Cardiovascular health: This term is defined as conditions associated with unwanted platelet aggregation, such as: artherosclerosis, myocardial infarction, stroke, thrombosis, peripheral artery disease, or decreased cerebral blood flow, and also includes diabetes (Type 1 or Type 2) and its associated cardiovascular problems.

Healthy Person—for purposes of this invention, a healthy person has not been diagnosed with, nor is aware of any cardiovascular health problems which are related to unwanted platelet aggregation, artherosclerosis, myocardial infarction, stroke, thrombosis, peripheral artery disease, decreased cerebral blood flow, or diabetes (either Type 1 or Type 2).

Preferred Compositions

A preferred WSTE comprises a tomato extract which is substantially lycopene-free, substantially heat stable and comprises water soluble compounds that have activity for preventing platelet aggregation and which have a molecular weight of less than 1000 daltons.

Preferably the WSTE comprises a, some or each of the water soluble compounds with activity for preventing platelet aggregation selected from the group comprising:

- (a) glycosylated phenolic acids or phenolic esters, or derivatives thereof
- (b) glycosylated flavonoids; and
- (c) nucleosides.

It is preferred that the WSTE used according to the invention is a tomato extract described in WO2010/049707. Preferably the WSTE is made according to the methods described in WO2010/049707. For instance, in some embodiments the WSTE may be made according to the methods described in Figures 2 or 4 of WO2010/049707.

In one embodiment the WSTE is a liquid in the form of a syrup.

A preferred extract has a browning index of < 0.8 AU, a pH of 4.0-4.3 and a density of 1.15-1.20 and may be prepared by the steps of:

- (a) Preparing a start mix of homogenised tomato;
- (b) Separating a water soluble fraction from fruit solids;
- (c) filtration of the water soluble fraction to make the extract substantially lycopene-free; and
- (d) concentration of water soluble compounds with activity for preventing platelet aggregation in the filtration permeate using an evaporator.

In another embodiment sugars may be removed from the extract. It is preferred that such extracts contain < 1% sugar, and contain > 95% of the water soluble compounds with activity for preventing platelet aggregation that are contained in a start mix of homogenised tomatoes from which the WSTE is derived. Such extracts may be in the form of concentrated aqueous solutions or preferably in powder form. In a most preferred embodiment such an extract may be made by the steps of:

- (a) Preparing a start mix of homogenised tomato fruit, wherein the pH of the start mix does not exceed pH 5.5, the holding temperature of the start mix does not exceed 35°C and the start mix is diluted with water such that it comprises less than 33% solids;
- (b) Separating a water soluble fraction from fruit solids by a procedure that does not raise the temperature of the fraction above 60 °C;
- (c) filtration of the water soluble fraction;
- (d) removal of free sugars from the filtered water soluble fraction; and
- (e) concentration of water soluble compounds with activity for preventing platelet aggregation by a procedure that does not raise the temperature of the fraction above 60 °C;

Following step (e) the extract may be a concentrated aqueous solution containing < 1% sugar, and containing > 95% of water soluble compounds with activity for preventing platelet aggregation contained in the start mix. Such aqueous solutions may be dehydrated further to form a powder.

In some embodiments the WSTE may be provided in a composition that contains other molecules that are beneficial to human health. For instance, the composition may also contain nitrate or a precursor of nitric oxide. The nitrate is preferably from a source of dietary nitrate (for instance, and purely by way of example, a water-soluble extract from swiss chard, rocket, spinach, rhubarb, strawberry or lettuce). The composition may also comprise folic acid or a metabolite thereof (e.g. 5-methoxytetrahydrofolate or

tetrahydrofolate). Preferred compositions for use according to the present invention which comprise folic acid or a metabolite thereof and/or nitrate are described in WO2014/102546.

Subjects that benefit from WSTE treatment are preferably human subjects. The inventors have found that healthy persons and those with a pre-existing cardiovascular condition can benefit from taking WSTE if they are at risk of being exposed to particulate air pollution.

Use in healthy persons

In some embodiments the person is a healthy person. In preferred embodiments where the person ingests the WSTE of this invention prior to exposure to air pollution, the ingestion occurs at least 30 minutes to 1 hour prior to the exposure. In particularly preferred embodiments, the ingestion occurs at least 2 or at least 3 hours prior to exposure in order to ensure the food or food supplement containing the WSTE has been digested and that the WSTE active ingredients have entered the circulatory system at their optimum levels. In areas where air pollution occurs in sustained episodes (i.e. air pollution lasts more than one day), the WSTE should be taken prior to the first episode and at least daily during the air pollution episode. In other embodiments, the WSTE is taken at least daily during the portion of the year where air pollution episodes are likely to occur.

Another embodiment of this invention is a method of maintaining healthy blood flow, or minimizing the risk of platelet aggregation in a person exposed to particulate air pollution comprising administering to the person at risk of exposure an effective amount of WSTE prior to or during exposure to particulate air pollution.

In another aspect of this invention the person at risk generally enjoys good cardiovascular health, i.e. does not have known problems associated with cardiovascular health.

Another embodiment of this invention is the use of WSTE to non-therapeutically maintain healthy blood flow in a healthy person at risk of exposure to particulate matter type air pollution. Examples of non-therapeutic results include: decreasing the risk of appearing older due to skin care issues, particularly

wrinkles or hardening of the skin, and/or maintaining general well-being and balance of energies due to good blood circulation.

Other uses of the WSTE of this invention include:

- Maintaining healthy platelet function in the presence of air pollution;
- Maintaining a healthy blood circulation and blood flow in the presence of air pollution;
- Reducing the risk of an adverse cardiovascular condition, such as atherosclerosis, or thrombosis in the presence of particulate matter air pollution;
- Reducing the severity of cardiovascular diseases when exposed to particulate matter; and
- Reducing the risk of cardiovascular and respiratory illness in an air polluted environment.

Use in persons who already have cardiovascular disease

It has also been surprisingly found that WSTE shows a synergistic anti-platelet aggregation effect in the presence of both adenosine diphosphate (ADP) and PM. ADP, a natural platelet agonist stored in platelets, is released upon platelet activation; and it induces a strong initiation of platelet aggregation. PM also strongly induces platelet aggregation generally, and also further promotes the platelet aggregation induced by ADP. The combination of ADP plus PM is inducing a stronger platelet activation response than the sum of the individual platelet activation responses induced by ADP or PM alone. As shown in more detail in the Examples, we have found that WSTE inhibits both the platelet activity induced by PM present in air pollution, and surprisingly it also inhibits the ADP induced platelet aggregation when promoted by the presence of PM.

Thus the WSTE of this invention, if desired, can also be used in a population of people who have a history of cardiovascular health problems or diabetes, and therefore have ADP present in their circulating blood, and are also at risk of exposure to particulate air pollution. Thus, another embodiment of this invention is a method of maintaining cardiovascular health in persons who have a history of cardiovascular health problems and who are exposed to particulate air pollution or who are at risk of exposure to particulate air pollution comprising administering an effective amount of a WSTE extract to the person prior to exposure or during exposure to the particulate air pollution.

Another aspect of this invention is the use of WSTE to protect the user against the harmful cardiovascular effects of air pollution, preferably particulate matter air pollution. A person who is exposed to such air pollution or who is at risk of exposure to such air pollution can ingest WSTE and thereby protect him/herself against cardiovascular problems associated with air pollution.

Another aspect of this invention is a method of decreasing the risk of cardiovascular health problems associated with particulate air pollution induced platelet aggregation comprising administering WSTE to a person at risk of exposure to particulate air pollution.

Another aspect of this invention is the use of water soluble tomato extract for the use in manufacturing a pharmaceutical or nutraceutical capable of maintaining cardiovascular health, lessening the risk of developing a cardiovascular health problem, or reducing the likelihood of worsening an existing cardiovascular health problem in a person who is exposed or is at risk of exposure to particulate air pollution.

DOSAGES AND FORMULATIONS

Doses:

Tomato Extract: Preferably, FRUITFLOW® 2 (a powder form) is used, although FRUITFLOW 1 (a liquid form) may be preferable if the formulation is to be liquid. The amount of WSTE should be from 25-300 mg/day preferably from 75-200 mg/day, and more preferably 125-175 mg/day. In some embodiments, 100 or 150 mg/day may be consumed by a subject. The aforementioned amounts may be taken as a single once-a-day dose, or partial dosages may be taken more than once a day (i.e. 2 or 3 times per day) so that the full dose is consumed. Preferred dosage forms according to the invention comprise 25-300 mg of WSTE, preferably 75-200 mg of WSTE and more preferably 125-175 mg of WSTE.

Timing of the dosage: It is preferable to consume WTSE prior to exposure to the air pollution episode, preferably at least 2-3 hours prior, so that the WTSE is properly metabolized and is available in the circulatory system prior to the exposure. In other embodiments, the ingestion occurs at least 30 minutes to 1 hour prior to the exposure. In areas where air pollution occurs in sustained episodes (i.e. air pollution lasts more than one day), the WSTE should be taken prior to the first episode and at least

daily during the air pollution episode. In other embodiments, the WSTE is taken at least daily during the portion of the year where air pollution episodes are likely to occur.

Forms

In one embodiment the compositions of the invention may be in the form of a nutraceutical. The term "nutraceutical" as used herein denotes usefulness in both nutritional and pharmaceutical fields of application. Thus, nutraceutical compositions comprising WSTE can be used as supplements to food and beverages and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations, such as capsules or tablets, or liquid formulations, such as solutions or suspensions.

The WSTE nutraceutical compositions according to the present invention may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film-forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilising agents (oils, fats, waxes, lecithins etc.), adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste-masking agents, weighting agents, gelling agents, gel-forming agents, antioxidants and antimicrobials.

The nutraceutical compositions according to the present invention may be in any galenic oral form containing a conventional carrier material that is suitable for administering to the body, e.g. in solid forms such as (additives/supplements for) food, food premix, fortified food, tablets, pills, granules, dragées, capsules and effervescent formulations, such as powders and tablets, or in liquid forms, such as solutions, emulsions or suspensions as e.g. beverages, pastes and oily suspensions. The pastes may be incorporated in hard- or soft- shell capsules, whereby the capsules feature e.g. a matrix of animal-derived gelatin, plant proteins or ligninsulfonate.

If the nutraceutical composition is a pharmaceutical formulation the composition further contains pharmaceutically acceptable excipients, diluents or adjuvants. Standard techniques may be used for their formulation, as e.g. disclosed in *Remington's Pharmaceutical Sciences, 20th edition* Williams & Wilkins, PA, USA. For oral administration, tablets and capsules are preferably used which contain a

suitable binding agent, e.g. gelatine or polyvinyl pyrrolidone, a suitable filler, e.g. lactose or starch, a suitable lubricant, e.g. magnesium stearate, and optionally further additives.

In some embodiments the compositions may be formulated for consumption as a food or drink. Examples of such foods or drinks are dairy products including, for example, margarines, spreads, butter, cheese, yoghurts or milk-drinks.

Other examples of foods that may be fortified with WSTE include bread, cereal bars, bakery items, such as cakes and cookies, and potato chips or crisps.

Beverages encompass non-alcoholic and alcoholic drinks as well as liquid preparations to be added to drinking water and liquid food. Non-alcoholic drinks are e.g., soft drinks, sports drinks, fruit juices, lemonades, teas and milk-based drinks. Liquid foods are e.g., soups and dairy products.

Nutraceutical compositions containing WSTE may be added to a soft drink, an energy bar, or a candy.

The non-limiting examples are presented to further illustrate the invention.

EXAMPLES

EXAMPLE 1

Reagents: Diesel Particulate Matter (Industrial Forklift, SRM2975) was from National Institute of Standards and Technology (Gaithersburg, MD, USA). Adenosine diphosphate (ADP), dimethyl sulfoxide (DMSO) and titanium(IV) oxide (TiO₂) anatase were from Sigma (Saint-Louis, MO). Phosphate buffered saline (PBS) was from Invitrogen (Carlsbad, CA).

Preparation of diesel particulate matter and TiO₂: Particles were suspended in DMSO and sonicated in a sonicating water bath for 5 min to minimize agglomeration. They were diluted at appropriate concentrations in PBS before use.

Platelet aggregation measurements: Blood from healthy human volunteers was collected through Safety-Multifly® needle into Sodium Citrate S-Monovette® tubes (Sarstedt, Nümbrecht, Germany). Platelet-rich plasma (PRP) was obtained by centrifugation of citrated blood at 150 g for 15 min at 37 °C. PRP were transferred into plastic tubes and left at 37°C. Remaining blood was centrifuged at 2000 g for 15 min at 37°C to obtain platelet-poor plasma (PPP). Platelet counts were determined using a Sysmex cell counter (Norderstedt, Germany) and the platelet number in PRP was adjusted to 3×10^8 platelets/mL with autologous PPP. PRP were incubated with Fruitflow®2 (86 µg/mL) or PBS at 37°C for 10 min prior to stimulation. The PRP suspensions were stimulated with ADP (2.5 µM), diesel particulate matter (50 µg/mL) or TiO₂ (50 µg/mL) in the presence or absence of Fruitflow® and the platelet aggregation was monitored on a platelet aggregometer (APACT 4004, Labitec, Ahrensburg, Germany) for 10 min at 37°C under stirring conditions. PPP was used to determine the baseline (100% aggregation). As particles can impact the light transmission, PPP with diesel particulate matter (50 µg/mL) or TiO₂ (50 µg/mL) was used as baseline in the presence of respectively diesel particulate matter or TiO₂. The platelet aggregation was quantified as area under the aggregation curve (AUC) and as the maximal percent aggregation (max % aggr.).

Results

ADP is a natural platelet agonist stored in platelets and is released upon platelet activation; it induces a strong initiation of platelet aggregation. Diesel particulate matter (PM) also strongly induces platelet aggregation. In contrast, non-polluted TiO₂ particles did not induce significant aggregation at equivalent concentrations. Moreover PM further promoted the platelet aggregation induced by ADP. The combination of ADP plus PM is inducing a stronger platelet activation response than the sum of the individual platelet activation responses induced by ADP or PM alone.

Interestingly Fruitflow® was also able to inhibit the platelet aggregation induced by PM. Thus the area under the aggregation curve (AUC) was significantly decreased by 30% from 18606 to 13079 and the maximal percent aggregation (max % aggr.) was significantly decreased by 28% from 37% to 27% in the presence of Fruitflow® (Table 1 and Figure 1). Finally, the platelet aggregation which is promoted by the combination of ADP and PM is strongly inhibited by Fruitflow®. The area under the aggregation curve (AUC) was significantly decreased by 36% from 55622 to 35511. The maximal percent aggregation (max %

aggr.) was significantly decreased by 35% from 101% to 66% in the presence of Fruitflow® (Table 1 and Figure 2)

Table 1: Effect of Fruitflow® on platelet aggregation induced by air pollution particulate matter

	ADP	ADP+FF	PM	PM+FF	PM+ADP	PM+ADP+FF
AUC	27953 ± 4856	6656 ± 1246*	18606 ± 2207	13079 ± 683*	55622 ± 3288	35511 ± 4297*
Max % aggr.	54 ± 7	18 ± 5*	37 ± 4	27 ± 1*	101 ± 7	66 ± 8*

All values are mean ± SD. ADP, Adenosine diphosphate. PM, particulate matter. FF, Fruitflow®. AUC, area under the aggregation curve. Max % aggr., maximal percent aggregation.

*p<0.05 significantly different from the respective treatment not receiving FF (e.g. ADP vs. ADP+FF, PM vs PM+FF, PM+ADP vs PM+ADP+FF).

Conclusion

Fruitflow® inhibits the platelet activity induced by PM present in air pollution. Moreover, Fruitflow® also inhibits the ADP induced platelet aggregation when promoted by the presence of PM.

Thus, Fruitflow® reduces the platelet activation induced by PM which promote arterial thrombosis, atherosclerosis, and other cardiovascular diseases. Fruitflow® may be particularly useful in case of already elevated platelet reactivity due to stress. Furthermore, the WTSE can be used in persons with a preexisting disease such as diabetes or cardiovascular disease as the platelet reactivity which is increased by natural platelet agonist released under stress conditions and disease such as ADP are further promoted by air pollutants such as PM and can be inhibited by Fruitflow® such reducing the risk of cardiovascular events induced by PM. In conclusion, Fruitflow® is able to reduce the deleterious effects of PM on the cardiovascular system.

CLAIMS:

1. A composition comprising a water soluble tomato extract (WSTE) for use in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.
2. The composition according to claim 1 for use in the form of a pharmaceutical, nutraceutical, food supplement or food.
3. The composition according to claim 1 or 2 for use in a human subject.
4. The composition according to claim 3 for use wherein the human subject is a healthy person.
5. The composition according to claim 3 for use wherein the human subject is a person with an existing cardiovascular disease.
6. The composition according to any preceding claim for use wherein the subject is exposed, or is at risk of exposure, to particulate air pollution which is formed as a result of: volcanic emissions, dust storms, forest fires, smoke from grassland fires, automotive emissions, manufacturing emissions or smoking.
7. The composition according to any preceding claim for use wherein the WSTE comprises a tomato extract which is:
 - (i) substantially lycopene-free;
 - (ii) substantially heat stable; and
 - (ii) comprises water soluble compounds that have activity for preventing platelet aggregation and which have a molecular weight of less than 1000 daltons.

8. The composition according to claim 7 for use wherein the WSTE comprises a, some or each of the water soluble compounds with activity for preventing platelet aggregation selected from:

- (a) glycosylated phenolic acids or phenolic esters, or derivatives thereof;
- (b) glycosylated flavonoids; and
- (c) nucleosides.

9. The composition according to claim 7 or 8 for use wherein the WSTE component has a browning index of < 0.8 AU, a pH of 4.0-4.3 and a density of 1.15-1.20.

10. The composition according to claim 7 or 8 for use wherein the WSTE component is a concentrated aqueous solution containing < 1% sugar, and containing > 95% of the water soluble compounds with activity for preventing platelet aggregation contained in a start mix of homogenised tomatoes from which the WSTE is derived.

11. The composition according to claim 7 or 8 for use wherein the WSTE component contains < 1% sugar, and contains > 95% of the water soluble compounds with activity for preventing platelet aggregation contained in a start mix of homogenised tomatoes from which the WSTE is derived and which is in powder form.

12. The composition according to any preceding claim for use wherein the composition comprises a quantity of WSTE which is sufficient to decrease, or minimize the risk of, platelet aggregation in the subject exposed to particulate air pollution.

13. A dosage form comprising a medicament, nutraceutical, food supplement or food containing an effective amount of water soluble tomato extract (WSTE) for protecting against the adverse effects of particulate air pollution.

14. The dosage form according to claim 13 comprising comprise 25-300 mg of WSTE.

15. A method of maintaining cardiovascular health, lessening the risk of developing a cardiovascular health problem, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution comprising: administering to the person a protective amount of a water soluble tomato extract ("WSTE") prior to or concomitant with exposure to particulate matter air pollution.

1/1




Fig. 1




Fig. 2

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/077993

A. CLASSIFICATION OF SUBJECT MATTER
INV. A23L33/105 A61K36/81
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2011/212913 A1 (O'KENNEDY NIAMH [GB]) 1 September 2011 (2011-09-01) cited in the application paragraphs [0001], [0003], [0007] - [0010], [0018] - [0026], [0040], [0046] - [0068], [0099] - [0105], [0111] - [0118] tables 1,3,5 paragraphs [0287], [0300], [0305] -----	13,14
Y	US 2003/206983 A1 (DUTTA-ROY ASIM KANTI [GB]) 6 November 2003 (2003-11-06) paragraphs [0003], [0007] - [0008], [0011], [0020], [0024] - [0027], [0039], [0046] - [0047], [0054], [0059] table 1 examples 2,8,9 figure 1 -----	1-15
X	US 2003/206983 A1 (DUTTA-ROY ASIM KANTI [GB]) 6 November 2003 (2003-11-06) paragraphs [0003], [0007] - [0008], [0011], [0020], [0024] - [0027], [0039], [0046] - [0047], [0054], [0059] table 1 examples 2,8,9 figure 1 -----	13,14
Y	-----	1-15
	- / --	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 January 2018	23/01/2018
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Couzy, François

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/077993

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2006/035971 A1 (ARAI YOICHI [JP] ET AL) 16 February 2006 (2006-02-16) paragraphs [0001], [0007], [0010] - [0012], [0019], [0036], [0038], [0040], [0043], [0062] - [0063]	13,14
Y	A. J. LUCKING ET AL: "Diesel exhaust inhalation increases thrombus formation in man", EUROPEAN HEART JOURNAL, vol. 29, no. 24, 24 October 2008 (2008-10-24), pages 3043-3051, XP055330824, GB ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehn464 cited in the application abstract tables 2-3 figures 1,2,3 page 3050	1-6, 12-15
Y	US 2013/023489 A1 (KUBOW STANLEY [CA] ET AL) 24 January 2013 (2013-01-24) paragraphs [0013], [0021], [0027] - [0029], [0042] - [0043]	1-15
A	US 2007/082071 A1 (WILLIMANN JOHN A [US]) 12 April 2007 (2007-04-12) paragraphs [0005], [0008], [0009], [0012], [0023], [0024]	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2017/077993

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 2011212913	A1 01-09-2011	EP 2355811 A2			17-08-2011
		US 2011212913 A1			01-09-2011
		US 2015105338 A1			16-04-2015
		WO 2010049709 A2			06-05-2010
<hr style="border-top: 1px dashed black;"/>					
US 2003206983	A1 06-11-2003	AT 245429 T			15-08-2003
		AU 772923 B2			13-05-2004
		CA 2330013 A1			04-11-1999
		DE 69909790 D1			28-08-2003
		DE 69909790 T2			22-04-2004
		DK 1083912 T3			17-11-2003
		EP 1083912 A1			21-03-2001
		EP 1334728 A2			13-08-2003
		ES 2204130 T3			16-04-2004
		JP 4975902 B2			11-07-2012
		JP 2002512972 A			08-05-2002
		JP 2012036195 A			23-02-2012
		PT 1083912 E			31-12-2003
		US 2003206983 A1			06-11-2003
		WO 9955350 A1			04-11-1999
<hr style="border-top: 1px dashed black;"/>					
US 2006035971	A1 16-02-2006	AU 2003261903 A1			07-06-2004
		EP 1559421 A1			03-08-2005
		KR 20050073611 A			14-07-2005
		US 2006035971 A1			16-02-2006
		US 2008188563 A1			07-08-2008
		WO 2004041265 A1			21-05-2004
<hr style="border-top: 1px dashed black;"/>					
US 2013023489	A1 24-01-2013	CA 2785581 A1			30-06-2011
		EP 2515925 A1			31-10-2012
		US 2013023489 A1			24-01-2013
		WO 2011075843 A1			30-06-2011
<hr style="border-top: 1px dashed black;"/>					
US 2007082071	A1 12-04-2007	US 2007082071 A1			12-04-2007
		WO 2008045449 A2			17-04-2008